Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients

Bibliography

• ENGER C, GRAHAM N, PENG Y et al.: Survival from early, intermediate, and late stages of HIV infection. JAMA (1996) 275:1329-1334.
   PubMed Web of Science ®Google Scholar
• MONTANER JS, REISS P, COOPER D et al.: Randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trail. Italy, the Netherlands, Canada and Australia Study. JAMA (1998) 279:930-937.
   PubMed Web of Science ®Google Scholar
• LAFEUILLADE A, POGGI C, TAMALET C, PROFIZI N, TOURRES C, COSTES O: Effects of a combination of zidovudine, didanosine, and lamivudine on primary human Immunodeficiency virus type 1 infection. J. Infect. Dis. (1997) 175:1051-1055.
   PubMed Web of Science ®Google Scholar
• MURPHY RL, BRUN S, HICKS C, ERON JJ et al.: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. AIDS (2001) 15:F1-F9.
   PubMed Web of Science ®Google Scholar
• YENI PG, HAMMER SM, HIRSCH MS et al.: Treatment for adult HIV infection 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 292:251-265.
   PubMed Web of Science ®Google Scholar
• BRAITHWAITE RS, JUSTICE AC, CHANG CC et al.: Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am. J. Med. (2005) 118:890-898.
   PubMed Web of Science ®Google Scholar
• THE ‘ABCS’ OF HIV PREVENTION: Report of a USAID technical meeting on behavior change approaches to primary prevention of HIV/AIDS (2002).
   Google Scholar
• DONCEL G, MAUCK C: Vaginal microbicides: a novel approach to preventing sexual transmission of HIV. Curr. HIV/AIDS Rep. (2004) 1:25-32.
   PubMedGoogle Scholar
• YEDERY RD, REDDY KV: Antimicrobial peptides as microbicidal contraceptives: prophecies for prophylactics-a mini review. Eur. J. Contracept. Reprod. Health Care (2005) 10:32-42.
   PubMed Web of Science ®Google Scholar
• HARRO CD, JUDSON FN, GORSE GJ et al.; FOR THE VAX004 STUDY GROUP: Recruitment and baseline epidemiologic profile of participants in the first Phase III HIV vaccine efficacy trial. J. Acquir. Immune Defic. Syndr. (2004) 37:1385-1392.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: UNAIDS collaborative group on cost-effectiveness, delivery and future access to HIV vaccines. Cost effectiveness and delivery study for future HIV vaccines. AIDS (2005) 19:W1-W6.
   Google Scholar
• YOULE M, WAINBERG MA et al.: Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J. Int. Assoc. Physicians AIDS Care (Chic Ill). (2003) 2:102-105.
   Google Scholar
• MELLORS JW, MUÑOZ A, GIORGI JV et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. (1997) 126:946-954.
   PubMed Web of Science ®Google Scholar
• MONTANER J, WAINBERG M: INCAS study results. In: Proceedings of the Public Meeting of the NIH Panel to Define Principles of Therapy of HIV Infection. Office of AIDS Research, NIH, Washington DC, USA (1996).
   Google Scholar
• D’AQUILA RT, HUGHES MD, JOHNSON VA et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann. Intern. Med. (1996) 124:1019-1030.
   PubMed Web of Science ®Google Scholar
• RELIQUET V, FERRE V, HASCOET C et al.; THE VIRGO STUDY TEAM: Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients. Antivir Ther. (1999) 4(Suppl. 3):83-84.
   PubMedGoogle Scholar
• EL-SADR WM, MULLIN CM, CARR A et al.: Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. (2005) 6:114-121.
   PubMed Web of Science ®Google Scholar
• BROWN TT, LI X, COLE SR, KINGSLEY LA et al.: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS (2005) 19:1375-1383.
   PubMed Web of Science ®Google Scholar
• LEVY AR, MCCANDLESS L, HARRIGAN PR et al.: Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis. (2005) 4:4.
   PubMedGoogle Scholar
• BARBARO G: Reviewing the cardiovascular complications of HIV Infection after the introduction of highly active antiretroviral therapy. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2005) 5:337-343.
   PubMedGoogle Scholar
• SQUIRES KE: An introduction to nucleoside and nucleotide analogues. Antivir Ther. (2001) 6(Suppl. 3):1-14.
   PubMedGoogle Scholar
• HAVLIR DV, TIERNEY C, FRIEDLAND GH et al.: In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. (2000) 182:321-325.
   PubMed Web of Science ®Google Scholar
• IMHOF A, LEDERGERBER B, GUNTHARD HF, HAUPTS S, WEBER R, SWISS: HIV Cohort Study. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin. Infect. Dis. (2005) 41:721-728.
   PubMed Web of Science ®Google Scholar
• BONNET F, BALESTRE E, BERNARDIN E, PELLEGRIN JL, NEAU D, DABIS F; GROUPE D’EPIDEMIOLOGIE CLINIQUE DU SIDA EN AQUITAINE: Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999-2003. Antivir. Chem. Chemother. (2005) 16:63-67.
   PubMedGoogle Scholar
• MCCOMSEY GA, WARD DJ, HESSENTHALER SM et al.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin. Infect. Dis. (2004) 38:263-270.
   PubMed Web of Science ®Google Scholar
• MOCROFT A, VELLA S, BENFIELD TL et al.: Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet (1998) 352:1725-1730.
   PubMed Web of Science ®Google Scholar
• SORIANO V, DE MENDOZA C: Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clin. Trials. (2002) 3:249-257.
   PubMedGoogle Scholar
• GOUJARD C, VINCENT I, MEYNARD JL et al.: Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. (2003) 47:118-123.
   PubMed Web of Science ®Google Scholar
• MARTIN A, MALLON PW: Therapeutic approaches to combating lipoatrophy: do they work? J. Antimicrob. Chemother. (2005) 55:612-615.
   PubMed Web of Science ®Google Scholar
• CLAY PG: The abacavir hypersensitivity reaction: a review. Clin. Ther. (2002) 24:1502-1514.
   PubMed Web of Science ®Google Scholar
• MOYLE G, SAWYER W, LAW M, AMIN J, HILL A: Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin. Ther. (2004) 26:92-97.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, KATOH I, KURATA S: Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization. Eur. J. Biochem. (2002) 269:2782-2788.
   PubMedGoogle Scholar
• PAUWELS R, BALZARINI J, SCHOLS D et al.: Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. (1988) 32:1025-1030.
   PubMed Web of Science ®Google Scholar
• ROBBINS BL, SRINIVAS RV, KIM C, BISCHOFBERGER N, FRIDLAND A: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2- phosphono-methoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. (1998) 42:612-617.
   PubMed Web of Science ®Google Scholar
• HAWKINS T, VEIKLEY W, ST CLAIRE RL, GUYER B, CLARK N, KEARNEY BP: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. (2005) 39:406-411.
   PubMed Web of Science ®Google Scholar
• KEARNEY BP, FLAHERTY JF, SHAH J: Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. (2004) 43:595-612.
   PubMed Web of Science ®Google Scholar
• BOFFITO M, BACK D, STAINSBY-TRON M et al.: Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-infected subjects. Br. J. Clin. Pharmacol. (2005) 59:38-42.
   PubMedGoogle Scholar
• RAY AS, OLSON L, FRIDLAND A: Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. (2004) 48:1089-1095.
   PubMed Web of Science ®Google Scholar
• TORTI C, QUIROS-ROLDON E, REGAZZI M et al.; KARINA-SISTHER COLLABORATION GROUP OF THE MASTER COHORT: Early virological failure after tenofovir + didanosine + efavirenz combination in hiv-positive patients upon starting antiretroviral therapy. Antivir. Ther. (2005) 10:505-513.
   PubMed Web of Science ®Google Scholar
• TABURET AM, PIKETTY C, CHAZALLON C et al.: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48:2091-2096.
   PubMed Web of Science ®Google Scholar
• BARDITCH-CROVO P, DEEKS SG, COLLIER A et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2001) 45:2733-2739.
   PubMed Web of Science ®Google Scholar
• LOUIE M, HOGAN C, HURLEY A et al.: Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS (2003) 17:1151-1156.
   PubMed Web of Science ®Google Scholar
• SQUIRES K, POZNIAK AL, PIERONE G JR et al.: Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann. Intern. Med. (2003) 139:313-320.
   PubMed Web of Science ®Google Scholar
• Tenofovir: new indication. For first-line antiretroviral therapy: wait and see. Prescrire Int. (2004) 13:180-182.
   PubMedGoogle Scholar
• GALLANT JE, STASZEWSKI S, POZNIAK AL et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 292:191-201.
   PubMed Web of Science ®Google Scholar
• MARGOT NA, ISAACSON E, MCGOWAN I, CHENG AK, SCHOOLEY RT, MILLER MD: Genotypic and phenotypic analysis of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS (2002) 16:1227-1235.
   PubMed Web of Science ®Google Scholar
• WAINBERG MA, MILLER MD, QUAN Y et al.: In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. (1999) 4:87-94.
   PubMed Web of Science ®Google Scholar
• WINTERS MA, SHAFER RW, JELLINGER RA MAMTORA G, GINGERAS T, MERIGAN TC: Human immunodeficiency type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinsoine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother. (1997) 41:757-762.
   PubMed Web of Science ®Google Scholar
• HARRIGAN PR, STONE C, GRIFFIN P, NAJERA I et al.: Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J. Infect. Dis. (2000) 181:912-920.
   PubMed Web of Science ®Google Scholar
• GAZZARD B, DEJESUS E, CAMPO E et al.: The combination of tenofovir DF, emtricitabine, and efavirenz has significantly greater response versus fixed dose zidovudine/lamivudine and efavirenz in antiretroviral naïve patients: a 24 week preliminary analysis (oral presentation H-1137c). 44th International Conference on Antimicrobial Agents and Chemotherapy, (ACAAC), Washington DC, USA (2004).
   Google Scholar
• PODZAMCZER D, GATHE J, JOHNSON M et al.: Study 418: Once-daily versus twice-daily lopinavir in antiretroviral-naïve patients: 24-week results. 9th European AIDS Conference, Warsaw, Poland (2003).
   Google Scholar
• PADILLA S, GUTIERREZ F, MASIA M, CANOVAS V, OROZCO C: Low frequency of renal function impairment during one-year therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS (2005) 19:421-424.
   PubMed Web of Science ®Google Scholar
• ANTONIOU T, RABOUD J, CHIRHIN S et al.: Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. (2005) 6:284-290.
   PubMed Web of Science ®Google Scholar
• IZZEDINE H, HULOT JS, VITTECOQ D et al.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. (2005) 20:743-746.
   PubMed Web of Science ®Google Scholar
• MAUSS S, BERGER F, CARLS H, SCHMUTZ G: Tenofovir is associated with mild renal dysfunction. XV International AIDS Conference, Bangkok, Thailand (2004).
   Google Scholar
• POWDERLEY W, COHEN C, GALLANT J, LU B, CHENG A, STUDY 903 TEAM: Similar incidence of osteopenia and osteoporosis in ART-naïve patients treated with tenofovir DF or stavudine in combination with lamivudine and efavirenz over 144 weeks. 12th Conference on Retroviruses and Opportunist Infections, Boston, MA, USA (2005).
   Google Scholar
• WANG LH, BEGLEY J, ST CLAIRE RL III, HARRIS J, WAKEFORD C, ROUSSEAU FS: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res. Hum. Retroviruses. (2004) 20:1173-1182.
   PubMed Web of Science ®Google Scholar
• MOLINA JM, COX SL: Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today (2005) 41:241-252.
   PubMed Web of Science ®Google Scholar
• CAHN P: Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. Expert Opin. Investig. Drugs (2004) 13:55-68.
   PubMed Web of Science ®Google Scholar
• MOLINA JM, JOURNOT V, MORAND-JOUBERT L et al.: Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J. Infect. Dis. (2005) 191:830-839.
   PubMed Web of Science ®Google Scholar
• SAAG MS, CAHN P, RAFFI F et al.: Efficacy and safety of emtricitabine versus stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA (2004) 292:180-189.
   PubMed Web of Science ®Google Scholar
• NELSON M, SCHIAVONE M: Emtricitabine (FTC) for the treatment of HIV infection. Int. J. Clin. Pract. (2004) 58:504-510.
   PubMed Web of Science ®Google Scholar
• BENSON CA, VAN DER HORST C, LAMARCA A et al.: A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS (2004) 18:2269-2276.
   PubMedGoogle Scholar
• BLUM MR, BEGLEY J, ZONG J et al.: Lack of pharmacokinetic interaction between emtricitabine and tenofovir DF when co-administered to steady-state in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2003) Poster A-1621.
   Google Scholar
• KEARNEY BP, ZONG J, BEGLEY J et al.: Bioequivalence of combination tenofovir DF/emtricitabine tablets for one-pill once daily administered. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy (2004). Poster 7.3.
   Google Scholar
• ARRIBAS JR: Tenofovir + FTC versus AZT/3TC fixed dose Combivir in art-naïve: 48 weeks final results. 18th International Conference on Antiviral Research (ICAR), Barcelona, Spain (2005).
   Google Scholar
• POZNIAK AL, GALLANT JE, DEJESUS E; FOR THE STUDY 904 TEAM: Superior outcome for tenofovir DF, emtricitabine and efavirenz compared to fixed dose zidovudine/lamivudine and EFV in antiretroviral naïve patients. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005) Abstract WeOa0202.
   Google Scholar
• MOYLE G, SABIN C, CARTLEDGE J et al.: A 48-week, randomised, open-label comparative study of tenofovir DF versus abacavir as substitutes for a thymidine analogue in persons with lipoatrophy and sustained virological suppression on HAART. 12th Conference on Retroviruses and Opportunist Infections (CROI). Boston, MA, USA (2005) Abstract 44LB.
   Google Scholar
• SCHOOLEY RT, RUANE P, MYERS RA et al.: Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS (2002) 16:1257-1263.
   PubMed Web of Science ®Google Scholar
• MOLINA JM, FERCHAL F, RANCINAN C et al.: Once-daily combination therapy with emtricitabine, didanosine, and efivirenz in human immunodeficiency virus-infected patients. J. Infect. Dis. (2000) 182:599-602.
   PubMed Web of Science ®Google Scholar
• SANNE I, MOMMEJA-MARIN H, HINKLE J et al.: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J. Infect. Dis. (2005) 191(6):825-829.
   PubMed Web of Science ®Google Scholar